• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form S-3/A filed by Tempest Therapeutics Inc.

    1/24/25 4:35:25 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TPST alert in real time by email
    S-3/A 1 d873142ds3a.htm S-3/A S-3/A

    As filed with the Securities and Exchange Commission on January 24, 2025

    Registration No. 333-280918

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    Pre-Effective Amendment No. 1

    to

    FORM S-3

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    TEMPEST THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   45-1472564
    (State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification Number)

    2000 Sierra Point Parkway, Suite 400

    Brisbane, California, 94005

    (415) 798-8589

    (Address, including zip code, and telephone number, including area code of registrant’s principal executive offices)

     

     

    Stephen Brady

    Chief Executive Officer

    2000 Sierra Point Parkway, Suite 400

    Brisbane, California, 94005

    (415) 798-8589

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

    Laura Berezin

    Jaime Chase

    Cooley LLP

    1700 Seventh Avenue, Suite 1900

    Seattle, Washington 98101

    (206) 452-8756

     

     

    From time to time after the effective date of this Registration Statement

    (Approximate date of commencement of proposed sale to the public)

     

     

    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. ☒

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☐

     

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

    The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment that specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

     

     

     


    Explanatory Note

    This Amendment No. 1, or the Amendment, is being filed to amend the Registration Statement on Form S-3 (File No. 333-280918), originally filed by the registrant on July 19, 2024, or the Registration Statement, to (i) modify the amount of remaining unsold securities to be included on the Registration Statement pursuant to Rule 415(a)(6) that were registered on a previously filed registration statement, as indicated in Exhibit 107 to this Amendment; (ii) to file an updated consent of Ernst & Young LLP, the registrant’s independent registered public accounting firm; and (iii) to update the exhibit listing set forth in Item 16. Accordingly, this Amendment No. 1 consists only of the facing page, this explanatory note, Part II of the Registration Statement, the signature page to the Registration Statement, and the exhibits being filed with this Amendment. The remainder of the Registration Statement, including the prospectus, is unchanged and has been omitted.


    PART II

    INFORMATION NOT REQUIRED IN PROSPECTUS

    Item 14. Other Expenses of Issuance and Distribution

    The following table sets forth the estimated costs and expenses, other than underwriting discounts and commissions, payable by us in connection with the offering of the securities being registered. All the amounts shown are estimates, except for the SEC registration fee and the FINRA filing fee.

     

    SEC registration fee

       $ 45,930  

    Accounting fees and expenses

         (1 ) 

    Legal fees and expenses

         (1 ) 

    Transfer agent fees and expenses

         (1 ) 

    Trustee fees and expenses

         (1 ) 

    Printing and miscellaneous expenses

         (1 ) 
      

     

     

     

    Total

       $ (1 )
      

     

     

     

     

    (1)

    These fees are calculated based on the securities offered and the number of issuances and accordingly cannot be estimated at this time.

    Item 15. Indemnification of Officers and Directors

    Section 145 of the Delaware General Corporate Law, or the DGCL, provides that a corporation may indemnify directors and officers as well as other employees and individuals against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with any threatened, pending or completed actions, suits or proceedings in which such person is made a party by reason of such person being or having been a director, officer, employee or agent of the registrant. The DGCL provides that Section 145 is not exclusive of other rights to which those seeking indemnification may be entitled under any bylaws, agreement, vote of stockholders or disinterested directors or otherwise. The registrant’s amended certificate of incorporation and amended and restated bylaws provide for indemnification by the registrant of its directors and officers to the fullest extent permitted by the DGCL.

    Section 102(b)(7) of the DGCL permits a corporation to provide in its certificate of incorporation that a director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (1) for any breach of the director’s duty of loyalty to the corporation or its stockholders, (2) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (3) for unlawful payments of dividends or unlawful stock repurchases redemptions or other distributions or (4) for any transaction from which the director derived an improper personal benefit. The registrant’s amended certificate of incorporation provides for such limitation of liability to the fullest extent permitted by the DGCL.

    The registrant has entered into indemnification agreements with each of its directors and executive officers to provide contractual indemnification in addition to the indemnification provided in its restated certificate of incorporation. Each indemnification agreement provides for indemnification and advancements by the registrant of certain expenses and costs relating to claims, suits or proceedings arising from his or her service to the registrant or, at our request, service to other entities, as officers or directors to the maximum extent permitted by applicable law. The registrant believes that these provisions and agreements are necessary to attract qualified directors.

    The registrant also maintains standard policies of insurance under which coverage is provided (1) to its directors and officers against loss arising from claims made by reason of breach of duty or other wrongful act, while acting in their capacity as directors and officers of the registrant and (2) to the registrant with respect to

     

    II-1


    payments which may be made by the registrant to such officers and directors pursuant to any indemnification provision contained in the registrant’s amended certificate of incorporation and amended and restated bylaws or otherwise as a matter of law.

    Item 16. Exhibits and Financial Statement Schedules

     

    Exhibit
    Number

      

    Description of Document

      1.1*    Form of Underwriting Agreement.
      1.2    Sales Agreement, dated June  20, 2024, between the Company and Jefferies LLC (incorporated by reference to Exhibit 1.1 of the Registrant’s Current Report on Form 8-K (File No.  001-35890), filed with the SEC on June 20, 2024).
      2.1    Agreement and Plan of Merger, dated as of March  29, 2021, by and among Tempest Therapeutics, Inc., Mars Merger Corp. and Tempest Therapeutics, Inc. (incorporated by reference to Exhibit 2.1 of the Registrant’s Current Report on Form 8-K (File No. 001-35890), filed with the SEC on March 29, 2021.
      3.1    Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-35890), filed with the SEC on May 15, 2019).
      3.2    Certificate of Amendment to the Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-35890), filed with the SEC on June 28, 2021).
      3.3    Certificate of Amendment to the Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-35890), filed with the SEC on June 28, 2021).
      3.5    Certificate of Designation of Series A Junior Participating Preferred Stock filed with the Secretary of State of the State of Delaware on October 10, 2023 (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K (File No. 35890), filed with the SEC on October 11, 2023).
      3.6    Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K (File No. 35890), filed with the SEC on September 24, 2021).
      4.1    Form of Tempest Therapeutics, Inc. Warrant to Purchase Stock (incorporated by reference to Exhibit  4.2 to the Registration Statement on Form S-4/A (File No. 333-255198) filed with the SEC on May 4, 2021).
      4.2    Registration Rights Agreement, dated April  26, 2022, by and among Tempest Therapeutics, Inc. and the persons party thereto (incorporated by reference to Exhibit 10.2 to Registrant’s Current Report on Form 8-K (File No. 001-35890) filed with the SEC on May 2, 2022).
      4.3    Rights Agreement, dated as of October  10, 2023, between Tempest Therapeutics, Inc. and Computershare Trust Company, N.A., which includes the form of Certificate of Designation as Exhibit A, the form of Right Certificate as Exhibit B and the Summary of Rights to Purchase Preferred Shares as Exhibit C (incorporated by reference to Exhibit 4.1 of Registrant’s Current Report on Form 8-K (File No. 001-35890), filed with the SEC on October 11, 2023).
      4.4    Amendment No. 1, dated as of October 9, 2024, to Rights Agreement, dated as of October 10, 2023, by and between Tempest Therapeutics, Inc. and Computershare Trust Company, N.A., as rights agent (incorporated by reference to Exhibit 4.1 of Registrant’s Current Report on Form 8-K (File No. 001-35890), filed with the SEC on October 10, 2024).

     

    II-2


      4.5    Amendment No. 2, dated as of December 5, 2024, to Rights Agreement, dated as of October 10, 2023, by and between Tempest Therapeutics, Inc. and Computershare Trust Company, N.A., as rights agent (incorporated by reference to Exhibit 4.1 of Registrant’s Current Report on Form 8-K (File No. 001-35890), filed with the SEC on December 6, 2024).
      4.6#    Form of Debt Indenture.
      4.7*    Form of Debt Securities.
      4.8*    Form of Common Stock Warrant Agreement and Warrant Certificate.
      4.9*    Form of Preferred Stock Warrant Agreement and Warrant Certificate.
      4.10*    Form of Debt Securities Warrant Agreement and Warrant Certificate.
      4.11*    Form of Specimen Preferred Stock Certificate and Certificate of Designations of Preferred Stock.
      4.12*    Form of Rights Agreement.
      4.13*    Form of Unit Agreement.
      5.1#    Opinion of Cooley LLP.
     23.1**    Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm to Tempest Therapeutics, Inc.
     23.3#    Consent of Cooley LLP (included in Exhibit 5.1).
     24.1#    Power of Attorney (included on signature page).
     25.1*    Statement of Eligibility of Trustee under the Indenture.
    107**    Filing Fee Table.

     

    *

    To be filed by amendment or by a report filed under the Exchange Act and incorporated herein by reference, if applicable.

     

    **

    Filed herewith.

     

    #

    Previously filed.

    Item 17. Undertakings

    The undersigned registrant hereby undertakes:

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

     

    II-3


    provided, however, that the undertakings set forth in paragraphs (1)(i), (1)(ii) and (1)(iii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are incorporated by reference in this registration statement or are contained in a form of prospectus filed pursuant to Rule 424(b) that is part of this registration statement.

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    (4) That, for the purpose of determining liability under the Securities Act to any purchaser:

    (i) Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and

    (ii) Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by Section 10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.

    (5) That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: (i) any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; (ii) any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; (iii) the portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and (iv) any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

    (6) That, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    II-4


    (7) That, for purposes of determining any liability under the Securities Act of 1933, (i) the information omitted from the form of prospectus filed as part of the registration statement in reliance upon Rule 430A and contained in the form of prospectus filed by the registrant pursuant to Rule 424(b)(l) or (4) or 497(h) under the Securities Act shall be deemed to be a part of the registration statement as of the time it was declared effective; and (ii) each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (8) To file an application for the purpose of determining the eligibility of the trustee to act under subsection (a) of Section 310 of the Trust Indenture Act in accordance with the rules and regulations prescribed by the Commission under Section 305(b)(2) of the Trust Indenture Act.

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

    II-5


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Brisbane, State of California, on this 24th day of January, 2025.

     

    TEMPEST THERAPEUTICS, INC.

    By:

      /s/ Stephen Brady
      Stephen Brady
      President and Chief Executive Officer

    Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities indicated below as of January 24, 2025.

     

    Signature

      

    Title

    /s/ Stephen Brady

    Stephen Brady

      

    President and Chief Executive Officer and Director

    (Principal Executive Officer)

    /s/ Nicholas Maestas

    Nicholas Maestas

      

    Chief Financial Officer

    (Principal Financial Officer)

    /s/ Justin Trojanowski

    Justin Trojanowski

      

    Corporate Controller, Treasurer

    (Principal Accounting Officer)

    *

    Michael Raab

      

    Chairman of the Board of Directors

    *

    Christine Pellizzari

      

    Director

    *

    Geoff Nichol, M.B., Ch.B., M.B.A.

      

    Director

    *

    Ronit Simantov, M.D.

      

    Director

     

    *By:

      /s/ Stephen Brady
      Stephen Brady
      Director
    Get the next $TPST alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TPST

    DatePrice TargetRatingAnalyst
    1/22/2026$11.00Neutral → Buy
    H.C. Wainwright
    4/10/2025Sector Outperform → Sector Perform
    Scotiabank
    4/10/2025Buy → Neutral
    H.C. Wainwright
    3/14/2024$13.00Sector Outperform
    Scotiabank
    2/8/2024$15.00Buy
    Jefferies
    10/21/2021Outperform
    William Blair
    7/13/2021$51.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $TPST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Tempest Therapeutics upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Tempest Therapeutics from Neutral to Buy and set a new price target of $11.00

    1/22/26 8:24:05 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tempest Therapeutics downgraded by Scotiabank

    Scotiabank downgraded Tempest Therapeutics from Sector Outperform to Sector Perform

    4/10/25 8:50:49 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tempest Therapeutics downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Tempest Therapeutics from Buy to Neutral

    4/10/25 8:03:29 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TPST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CEO and President Angel Matthew

    4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    2/6/26 4:26:13 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Angel Matthew claimed ownership of 8,268,495 shares (SEC Form 3)

    3 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    2/6/26 4:24:53 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Pellizzari Christine A

    4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    1/28/26 4:30:06 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TPST
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Brady Stephen R bought $73,850 worth of shares (35,000 units at $2.11), increasing direct ownership by 308% to 46,376 units (SEC Form 4)

    4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    7/8/24 4:15:11 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Whiting Samuel bought $9,951 worth of shares (4,672 units at $2.13), increasing direct ownership by 95% to 9,573 units (SEC Form 4)

    4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    7/3/24 7:35:42 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corporate Controller Trojanowski Justin bought $16,200 worth of shares (7,500 units at $2.16), increasing direct ownership by 51% to 22,168 units (SEC Form 4)

    4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    7/2/24 4:15:14 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TPST
    SEC Filings

    View All

    Tempest Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Changes in Control of Registrant

    8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)

    2/6/26 4:12:27 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Tempest Therapeutics Inc.

    8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)

    1/28/26 4:05:33 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Tempest Therapeutics Inc.

    SCHEDULE 13G - Tempest Therapeutics, Inc. (0001544227) (Subject)

    1/21/26 9:27:23 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TPST
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets

    All-stock transaction brings Tempest a portfolio of next-generation CAR-T assets, including TPST-2003, a clinical-stage dual-targeting CD-19/BCMA CAR-T with strategic partner-funded BLA filing in China planned for 2027Operational runway extended to mid-2027, supporting multiple potential value-generating milestonesMatt Angel, Ph.D., joins Tempest as President and CEOPreviously announced transaction closed following stockholder approval of share issuance at the 2025 Annual Meeting on January 27, 2026 BRISBANE, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company with a pipeline of advanced strategic therapeut

    2/4/26 4:47:13 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders

    BRISBANE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company with a pipeline of targeted and immune-mediated therapeutics to fight cancer, today announced the record date of January 30, 2026 (the "Record Date") for the distribution of warrants to purchase Tempest common stock ("Warrants") as a dividend (the "Warrant Dividends"), as contemplated by Tempest's previously announced Asset Purchase Agreement (the "Asset Purchase Agreement") with Erigen LLC and Factor Bioscience Inc. The distribution of the Warrant Dividends is expected to be Tuesday, February 3, 2026, but is subject to the prior satisfaction of c

    1/20/26 5:20:02 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

    BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced the closing of its previously announced registered direct offering priced at the market under Nasdaq rules for the purchase and sale of 1,172,414 shares of its common stock (or common stock equivalents), at an offering price of $3.625 per share of common stock (or common stock equivalent). Additionally, in a concurrent private placement, the Company issued and sold short-term unregistered warrants to purchase up to an aggregate of 1,172,414 shares of

    11/26/25 4:05:00 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TPST
    Leadership Updates

    Live Leadership Updates

    View All

    After Major Oncology Conference, All Eyes Turn to Industry Innovation

    USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- After the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and researchers are optimistic, especially in the fields of immunotherapy, Car T-cell therapy, liquid biopsies, breast cancer, AI, and even exercise. However, with reports coming out that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For inv

    6/12/25 9:00:00 AM ET
    $CAH
    $CTOR
    $CTXR
    Other Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs

    BRISBANE, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced the appointment of Sheldon Mullins as Vice President, Regulatory Affairs. Mr. Mullins' presence on the team builds upon the recent addition of Troy Wagner as Vice President of Quality Assurance, who brought additional late-stage experience to the company. Additionally, in connection with the plan to advance amezalpat into a pivotal study in first-line HCC patients and to reflect their roles in late-stage development, the titles of Darrin Bomba and Henry John

    9/18/24 8:00:00 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance

    BRISBANE, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced the appointment of Troy M. Wagner as Vice President of Quality Assurance. "Troy brings a wealth of experience in late-stage product development, including managing quality systems across a range of global clinical studies and assisting with global regulatory filings. We look forward to her contributions as we move towards Phase 3 development of amezalpat to treat hepatocellular carcinoma and are thrilled to have her join the Tempest leadership team,"

    8/21/24 8:00:00 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TPST
    Financials

    Live finance-specific insights

    View All

    Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders

    BRISBANE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company with a pipeline of targeted and immune-mediated therapeutics to fight cancer, today announced the record date of January 30, 2026 (the "Record Date") for the distribution of warrants to purchase Tempest common stock ("Warrants") as a dividend (the "Warrant Dividends"), as contemplated by Tempest's previously announced Asset Purchase Agreement (the "Asset Purchase Agreement") with Erigen LLC and Factor Bioscience Inc. The distribution of the Warrant Dividends is expected to be Tuesday, February 3, 2026, but is subject to the prior satisfaction of c

    1/20/26 5:20:02 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tempest Extends Limited Duration Stockholder Rights Plan

    BRISBANE, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest" or the "Company"), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that its Board of Directors (the "Board") has adopted an amendment to its existing limited duration stockholder rights plan (as amended, the "Rights Plan") to extend the duration of the Rights Plan until the Annual Meeting of Stockholders. "Given the significant milestones reached this year in the amezalpat program – the positive survival data compared to standard of care and broad agreement with FDA on the Phase 3 path – coupled

    10/10/24 7:00:00 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm

    21 months median OS in amezalpat arm vs. 15 in control arm 50% (20/40) of patients on amezalpat arm remain in survival follow up 0.65 hazard ratio, maintained since 0.59 observed in primary analysis 10 months earlier Early and persistent separation of survival curves OS is the primary regulatory endpoint for first-line HCCCompany to host webcast conference call today at 8:30am ET BRISBANE, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced new positive data from the ongoing global randomized Phase 1b/2 clinica

    6/20/24 8:00:00 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TPST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Tempest Therapeutics Inc.

    SC 13D/A - Tempest Therapeutics, Inc. (0001544227) (Subject)

    8/12/24 8:59:00 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Tempest Therapeutics Inc. (Amendment)

    SC 13D/A - Tempest Therapeutics, Inc. (0001544227) (Subject)

    5/13/24 4:54:01 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Tempest Therapeutics Inc. (Amendment)

    SC 13G/A - Tempest Therapeutics, Inc. (0001544227) (Subject)

    2/14/24 6:49:42 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care